Petter Stiff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Petter stiff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Petter Stiff Today - Breaking & Trending Today

BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients


BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients
Data receipt is ongoing and evaluation of efficacy data is underway
Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit
Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study there was a numerically lower number of deaths up to day 29 in the bemcentinib arm (1 of 28 with bemcentinib + standard of care vs 5 of 32 in patients treated with standard of care alone); in BGBC020 it was 2 vs 3 respectively
More detailed top line data expected to report in May ....

South Africa , United Kingdom , Chris Welsh , Carina Jurs , Mary Jane Elliott , Richard Godfrey , Prnewswire Bergenbio , Tom Wilkinson , Lucy Featherstone , International Media Relations , Consilium Strategic Communications , Oslo Stock Exchange , Professor Tom Wilkinson , Respiratory Medicine , Chief Investigator , Chief Executive Officer , Trial Synopsis , Jane Elliott , Petter Stiff , Crux Advisers , Norwegian Securities Trading , ஒன்றுபட்டது கிஂக்டம் , கிறிஸ் வெல்ஶ் , கரினா ஜூர்ஸ் , மேரி ஜேன் எலியட் , ரிச்சர்ட் காட்ஃப்ரே ,

BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021)


BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021)
BERGEN, Norway, March 6, 2021 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021.
The presentation was led by BerGenBio s collaborator, Professor Wendy Maury, Professor of Microbiology and Immunology at the University of Iowa (Iowa City, USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to infect cell lines from the human airway, increasing the amount of virus measured in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib r ....

South Africa , United States , United Kingdom , Wendy Maury , Chris Welsh , Carina Jurs , Richard Godfrey , Mary Jane Elliott , Prnewswire Bergenbio , Lucy Featherstone , University Of Iowa City , International Media Relations , Consilium Strategic Communications , Oslo Stock Exchange , Science Spotlight , Opportunistic Infections , Professor Wendy Maury , Iowa City , Jane Elliott , Petter Stiff , Crux Advisers , Norwegian Securities Trading , Co Vid , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , வெண்டி ம Ury ரி ,